Close X
Wednesday, November 20, 2024
ADVT 
National

A look at the rare blood clot condition VIPIT

Darpan News Desk The Canadian Press, 29 Mar, 2021 08:56 PM
  • A look at the rare blood clot condition VIPIT

Federal officials limited the use of Oxford-AstraZeneca's COVID-19 vaccine Monday while it announced an investigation into reported links to a rare blood clot condition known as VIPIT.

The National Advisory Committee on Immunization says the vaccine should not be used by people younger than age of 55, while Health Canada has issued guidelines around what to look for if you suspect you have had an adverse reaction.

Here’s a look at this rare condition.

WHAT IS VIPIT?

VIPIT stands for: Vaccine-Induced Prothrombotic Immune Thrombocytopenia. According to NACI, it is associated with the development of antibodies that "activate" platelets, which stimulate the formation of blood clots.

HOW DANGEROUS IS VIPIT?

The case fatality of VIPIT is approximately 40 per cent, however that may decrease with increased awareness and early treatment.

HOW COMMON IS THIS ADVERSE REACTION?

It’s not clear how common this happens after vaccination but the European Medicines Agency said March 18 it was originally believed to occur once per 1,000,000 people vaccinated with the AstraZeneca vaccine. However, a higher rate of 1 per 100,000 was reported in Germany.

WHO DOES THIS AFFECT?

So far, cases have largely been among women younger than age 55 and mostly emerged between four and 16 days after vaccination. However, a brief for Ontario’s COVID-19 advisory group notes many European countries used more of their initial AstraZeneca doses in women under age 55, which may have skewed the results.

The provincial science table experts add that VIPIT does not appear to be more common in people who have had blood clots before, have a family history of blood clots, have a low platelets, or pregnant women.

ARE THERE KNOWN CASES IN CANADA LINKED TO THE ASTRAZENECA VACCINE?

No.

WHAT ARE THE WARNING SIGNS?

Experts say to look for the following symptoms between four and 20 days after vaccination: a severe headache that does not go away; a seizure; difficulty moving part of your body; new blurry vision that does not go away; difficulty speaking; shortness of breath; chest pain; severe abdominal pain; new severe swelling, pain, or colour change of an arm or a leg.

MORE National ARTICLES

Top court won't review disclosure ruling

Top court won't review disclosure ruling
The Supreme Court of Canada will not review a judge's decision to grant author Steven Galloway access to emails between a woman who accused him of sexual assault and staff at the University of British Columbia.

Top court won't review disclosure ruling

Wage subsidy could cost less than expected

Wage subsidy could cost less than expected
Canada's official fiscal watchdog says the federal wage subsidy program might cost $14 billion less than the government predicted.

Wage subsidy could cost less than expected

WE Charity scales back operations

WE Charity scales back operations
WE Charity is scaling back its operations, making dozens of layoffs in Canada and the United Kingdom, while also looking to sell some of its real estate holdings in Toronto.

WE Charity scales back operations

Money to help communities adapt to COVID-19

Money to help communities adapt to COVID-19
The federal government is offering $31 million to help communities find ways to adapt to the realities of the COVID-19 pandemic.

Money to help communities adapt to COVID-19

More needed to protect politicians: McKenna

More needed to protect politicians: McKenna
Infrastructure Minister Catherine McKenna says new measures must be taken to protect Canadian politicians from threatening behaviour.

More needed to protect politicians: McKenna

Abbotsford Police are on the hunt for Lorne Joseph Guilbault.

Abbotsford Police are on the hunt for Lorne Joseph Guilbault.
Abbotsford Police are seeking public assistance to locate a man wanted on several outstanding arrest warrants.

Abbotsford Police are on the hunt for Lorne Joseph Guilbault.